Related Experiment Videos
Serum CA 19-9 and CA 50 antigens in hemodialysis patients
Insights
Serum tumor markers CA 19-9 and CA 50 are valuable for detecting cancer in hemodialysis patients. Unlike CEA, these markers maintain their clinical utility in chronic renal failure.
Area of Science:
- Oncology
- Nephrology
- Clinical Chemistry
Background:
- Chronic renal failure (CRF) impacts tumor marker levels.
- Carcinoid antigen (CEA) levels can be affected by renal function.
- CA 19-9 and CA 50 are tumor markers with potential utility in CRF.
Purpose of the Study:
- To evaluate the clinical utility of CA 19-9 and CA 50 in hemodialysis patients.
- To compare the performance of CA 19-9 and CA 50 with CEA in this population.
Main Methods:
- Serum concentrations of CA 19-9, CA 50, and CEA were measured.
- Patients were divided into uncomplicated hemodialysis (Group 1) and hemodialysis with cancer (Group 2).
Main Results:
- CA 19-9 and CA 50 demonstrated excellent specificity in uncomplicated hemodialysis patients.
- The sensitivity of CA 19-9 and CA 50 in hemodialysis patients with cancer was comparable to those with normal renal function.
- CEA performance was not detailed in comparison.
Conclusions:
- CA 19-9 and CA 50 retain their clinical value as tumor markers in patients with chronic renal failure.
- These markers offer a reliable alternative to CEA in the context of hemodialysis.
Abstract:
Serum concentrations of monoclonal antibody-defined tumor markers CA 19-9 and CA 50 were measured in 64 uncomplicated hemodialysis patients (Group 1) and in 8 hemodialysis patients with cancer (Group 2) in comparison with corresponding CEA determinations. From our results in Group 1 patients it appears that both CA 19-9 and CA 50 maintained an excellent specificity in these patients. As to the sensitivity of these tests, our findings in Group 2 patients are comparable with those reported in patients with cancer and normal renal function. It is concluded that, unlike CEA, these new tumor markers maintain their clinical value in chronic renal failure.